Zobrazeno 1 - 10
of 14
pro vyhledávání: '"Andrew Haydon"'
Autor:
Joshua D. Cohen, Lisa Dobbyn, Desmond Yip, Jeanne Tie, Maria Popoli, Peter Gibbs, Bert Vogelstein, Yuxuan Wang, Cristian Tomasetti, Iain Skinner, Janine Ptak, Kenneth W. Kinzler, Hui-Li Wong, Christos S. Karapetis, Natalie Silliman, Suzanne Kosmider, Nickolas Papadopoulos, Matthew Burge, Mary J. Schaeffer, Timothy J. Price, Rachel Wong, Lu Li, Andrew Haydon, Belinda Lee, Margaret Lee, Niall C. Tebbutt, Serigne Lo, Michael Christie
Publikováno v:
Int J Cancer
Studies in multiple solid tumor types have demonstrated the prognostic significance of ctDNA analysis after curative intent surgery. A combined analysis of data across completed studies could further our understanding of circulating tumor DNA (ctDNA)
Autor:
Tony Blakely, Kathryn Whitfield, Nina Afshar, Victoria White, Luc te Marvelde, Roger L. Milne, S. Ghazaleh Dashti, Rebecca J Bergin, Andrew Haydon, Jon Emery, Robert J. Thomas, Dallas R. English, Graham G. Giles
Publikováno v:
Cancer epidemiology, biomarkersprevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 30(10)
Background: Socio-economic inequalities in colon cancer survival exist in high-income countries, but the reasons are unclear. We assessed the mediating effects of stage at diagnosis, comorbidities, and treatment (surgery and intravenous chemotherapy)
Autor:
Michelle Frances Morris, Andrea Harkin, Martin R. Stockler, Eva Segelov, Timothy Iveson, Christine Aiken, Niall C. Tebbutt, Prunella Blinman, David Boadle, Andrew Haydon, Andrew J. Martin, David Goldstein, Michael Jefford
Publikováno v:
JNCI Cancer Spectrum
Background SCOT was an international, randomized phase 3 trial of 3 months vs 6 months of adjuvant chemotherapy with oxaliplatin and a fluoropyrimidine in patients with colorectal cancer. We sought patients’ preferences for 3 months vs 6 months of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::69ec577da178882f0af2cfb5e452f04c
Autor:
Cristian Tomasetti, Dusan Kotasek, Bert Vogelstein, Craig Underhill, Suzanne Kosmider, Julian Choi, Peter Gibbs, Adrian Fox, Wei Hong, Yuxuan Wang, Hui-Li Wong, Jeanne Tie, Christos S Karapetis, Niall C. Tebbutt, Joy Schaeffer, Benjamin N. J. Thomson, Lu Li, Andrew Haydon, Matthew Burge, Joshua D. Cohen, Jenny Shannon, Janine Ptak, Michael Christie, Kenneth W. Kinzler, Kathryn M. Field, Nicholas Papadopoulos, Rachel Wong
Publikováno v:
PLoS Medicine
PLoS Medicine, Vol 18, Iss 5, p e1003620 (2021)
PLoS Medicine, Vol 18, Iss 5, p e1003620 (2021)
Background In patients with resectable colorectal liver metastases (CRLM), the role of pre- and postoperative systemic therapy continues to be debated. Previous studies have shown that circulating tumor DNA (ctDNA) analysis, as a marker of minimal re
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ffca5f1804285e3c3daa386a9dc7debe
Autor:
Natallie Silliman, Suzanne Kosmider, Bert Volgestein, Desmond Yip, Hany Elsaleh, Madhu Sudan Singh, David Goldstein, Yuxuan Wang, Matthew Burge, Carolyn Bampton, Iain Skinner, Timothy J. Price, Christos S. Karapetis, Matthew Croxford, Jeanne Tie, Cristian Tomasetti, Ian T. Jones, Lu Li, Andrew Haydon, Rachel Wong, Michael Christie, David Rangiah, Joshua D. Cohen, Mary J Schaefer, Margaret Lee, Nickolas Papadopoulos, Peter Gibbs, Ben Tran, Kenneth W. Kinzler, Koen Simons, Jeanne Ptak, Isaac Kinde, Ian Faragher, Lisa Dobbyn
Publikováno v:
Flinders University PURE
ObjectiveFor patients with locally advanced rectal cancer (LARC), adjuvant chemotherapy selection following surgery remains a major clinical dilemma. Here, we investigated the ability of circulating tumour DNA (ctDNA) to improve risk stratification i
Autor:
Peter Carne, Lewis Au, Simon Wilkins, Andrew Haydon, Adrian L. Polglase, Stephen Bell, Karen Oliva, Roger Wale, Yoland Antill, P. Ranchod, Chip Farmer, Jeremy Shapiro, Matthew Grant, Martin Chin, Stewart Skinner, Paul J. McMurrick, Paul Simpson, Eva Segelov
Publikováno v:
International journal of surgery (London, England). 51
Background/Objectives Adjuvant chemotherapy for Stage II colon cancer offers a small (2-3%) overall survival benefit and is not universally recommended. Mismatch repair deficiency (dMMR) confers an improved prognosis identifying patients unlikely to
Autor:
Louise M. Nott, Sebastian Lunke, Craig Underhill, Jeremy Shapiro, Guy van Hazel, Eva Segelov, Kate Wilson, Timothy J. Price, Jayesh Desai, Michael Jefford, Subotheni Thavaneswaran, Nick Pavlakis, John Simes, Val Gebski, Fortunato Ciardiello, Lorraine A. Chantrill, Kristy P. Robledo, Mustafa Khasraw, Andrew Haydon, Paul Waring, Christos S. Karapetis, Elena Elez, Harpreet Wasan
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 34(19)
Purpose RAS mutations predict lack of response to epidermal growth factor receptor monoclonal antibody therapy in patients with metastatic colorectal cancer (mCRC), but preclinical studies and retrospective clinical data suggest that patients with tu
Autor:
Andrew Haydon, Simon Wilkins, Paul J. McMurrick, Margaret Staples, Karen Oliva, Peter Carne, Ian Porter, Stephen Bell
Publikováno v:
Diseases of the colon and rectum. 59(5)
Many studies have shown significantly improved outcomes (reduced local recurrence and improved overall survival) for patients achieving a complete pathological response from neoadjuvant chemoradiotherapy.This study aimed to document the complete path
Autor:
Chris Karapetis, Michael Jefford, Nadine M Magoski, Dongsheng Tu, Félix Couture, Michael B. Sawyer, Christopher J. O'Callaghan, Timothy J. Price, John Zalcberg, Derek J. Jonker, Ian Walters, Danielle Charpentier, Jeremy Shapiro, Jehan Siddiqui, John Simes, Jolie Ringash, Louise M. Nott, Malcolm J. Moore, Lillian L. Siu, Andrew Haydon, Winston Liauw
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 31(19)
Purpose The antiepidermal growth factor receptor monoclonal antibody cetuximab has improved survival in patients with metastatic, chemotherapy-refractory, wild-type K-RAS colorectal cancer. The addition of brivanib, a tyrosine kinase inhibitor target
Autor:
Helen L Kelsall, Graham G. Giles, David C. Muller, Dallas R. English, Laura Baglietto, Andrew Haydon
Previous research relating lower socioeconomic status (SES) with poorer survival from colorectal cancer has varied in adjustment for confounding factors and in the use of individual-level or aggregate-level indicators of SES. We investigated the effe
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0b3cf2e81d6659ea2b69d13aae5cdab4
http://hdl.handle.net/11568/817455
http://hdl.handle.net/11568/817455